Non Hodgkin Lymphoma Clinical Trial

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Summary

The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, participant-level data longitudinally in participants diagnosed with various subtypes of non-Hodgkin lymphoma (NHL).

View Full Description

Full Description

This Disease Registry is designed to capture the patient characteristics, practice patterns, and therapeutic strategies evaluated in community and academic centers when treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), R/R follicular lymphoma (FL), and primary mediastinal B-cell lymphoma (PMBCL). The data collected in this Registry will facilitate the evaluation of the current treatment landscape for non-Hodgkin lymphoma (NHL), including the clinical effectiveness, safety. No investigational product or drug will be administered as part of this study. Enrolled patients will receive treatment and evaluations for their disease according to the standard of care and routine clinical practice at each study site. All treatments that patients receive for their disease will be recorded, including any previous lymphoma treatments. Clinical outcomes will be documented as part of an objective clinical assessment. In addition, patient-reported health-related quality of life (HRQoL) outcomes data will be collected from patients using various validated instruments. Social support data will also be collected.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Must be ≥18 years of age at the time of consent
Must be able to provide written informed consent personally or by legally authorized representative

Must have 1 of the following histologically confirmed Non-Hodgkin Lymphoma (NHL) subtypes:

Diffuse large B-cell lymphoma (DLBCL), NOS; or DLBCL high-grade lymphoma, not otherwise specified (NOS); or DLBCL high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple-hit lymphoma)

Epstein-Barr virus-positive or composite DLBCL are allowed
Follicular lymphoma (FL)
Primary mediastinal B-cell lymphoma (PMBCL)
Must have been previously treated with ≥ 1 prior systemic therapy (e.g., chemotherapy, immunotherapy, or chemoimmunotherapy)
For first relapsed/refractory (R/R) DLBCL cohort, participant must have confirmed R/R disease and must have initiated 2L systemic treatment ≤ 60 days prior to enrollment
For second R/R DLBCL cohort, participant must have confirmed second R/R disease during or after 2L systemic treatment and must have initiated 3L systemic treatment ≤ 60 days prior to enrollment
For first R/R FL cohort, participant must have confirmed R/R disease (grade 1 to 3B or transformed) and must have initiated 2L systemic treatment ≤ 60 days prior to enrollment
For first R/R PMBCL cohort, participant must have confirmed first R/R disease during or after 1L systemic treatment and must have initiated 2L systemic treatment ≤ 60 days prior to enrollment
Participant must be willing and able to complete enrollment and follow-up health-related quality of life (HRQoL) and social support instruments
Participants volunteering for the Tissue Sub-Study must consent for use of their blood/tumor biopsies, which were collected as per standard of care, for exploratory analyses

Exclusion Criteria:

Participant whose prior start and end date of DLBCL, FL, or PMBCL treatment, and prior treatment received, including chemotherapy, radiation, surgery (not including excisional biopsies), and other anticancer therapy, are unknown
Participant who has any other active malignancy (non-DLBCL, non-PMBCL, or non-FL) for which the participant is receiving treatment at the time of enrollment or any other former malignancy that was diagnosed within 6 months prior to Registry enrollment (with the exception of non-melanoma skin cancer)
Currently enrolled in any interventional clinical trial where the participant is being treated with an investigational product that cannot be identified

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

1000

Study ID:

NCT04982471

Recruitment Status:

Recruiting

Sponsor:

Celgene

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 37 Locations for this study

See Locations Near You

Genesis Cancer Center
Hot Springs Arkansas, 71913, United States
VA Central California Health Care System - NAVREF - PPDS
Fresno California, 93703, United States More Info
Yuankai Lin, Site 129
Contact
559-225-6100
University of Florida College of Medicine Jacksonville
Jacksonville Florida, 32209, United States More Info
Walter Quan, Site 145
Contact
252-816-2560
Bond Clinic, P.A.
Winter Haven Florida, 33881, United States
Harbin Clinic
Rome Georgia, 30165, United States More Info
Dilawar Khan, Site 104
Contact
706-235-5875
Summit Cancer Care, PC
Savannah Georgia, 31401, United States
Cotton O'Neil Clinical Research, Hematology and Oncology
Topeka Kansas, 66606, United States
Tulane University Health Sciences Center
New Orleans Louisiana, 70112, United States More Info
Nakhle Saba, Site 152
Contact
504-988-5482
Regional Cancer Care Associates
Bethesda Maryland, 20817, United States
UPMC Western Maryland Corporation
Cumberland Maryland, 21502, United States
UPMC Western Maryland Corporation
Cumberland Maryland, 21502, United States More Info
Blanche Mavromatis, Site 101
Contact
University Of Michigan Comprehensive Cancer Center
Ann Arbor Michigan, 48109, United States More Info
Tycel Phillips, Site 147
Contact
University Of Minnesota
Minneapolis Minnesota, 55455, United States
Oncology Research, HealthPartners Institute
Saint Louis Park Minnesota, 55426, United States
Harry S. Truman Memorial Veterans' Hospital (HSTMVH) - NAVREF - PPDS
Columbia Missouri, 65201, United States More Info
Suzanne Patton, Site 144
Contact
Mercy Clinic Oncology and Hematology - Joplin
Joplin Missouri, 64804, United States More Info
Samir Dalia, Site 119
Contact
417-556-3063
Saint Louis University
Saint Louis Missouri, 63110, United States More Info
Sagun Goyal, Site 120
Contact
314-577-8854
Local Institution - 162
Reno Nevada, 89511, United States
Astera Cancer Care East Brunswick
East Brunswick New Jersey, 08816, United States More Info
Mohammad Kazemi, Site 159
Contact
Summit Medical Group
Florham Park New Jersey, 07932, United States More Info
William DeRosa, Site 132
Contact
973-538-5210
Atlantic Hematology Oncology - Morristown
Morristown New Jersey, 07960, United States
Rochester General Hospital - Lipson Cancer Institute
Rochester New York, 14621, United States
New York Medical College
Valhalla New York, 10595, United States More Info
Karen Seiter, Site 166
Contact
914-493-7514
East Carolina University
Greenville North Carolina, 27858, United States More Info
Darla Liles, Site 151
Contact
252-744-2391
Cleveland Clinic Mercy Hospital
Canton Ohio, 44708, United States More Info
Mitchell Haut, Site 113
Contact
330-453-9993
Tri County Hematology Oncology
Canton Ohio, 44718, United States
Tri County Hematology Oncology
Canton Ohio, 44718, United States More Info
Noman Rafique, Site 111
Contact
330-837-2646
Local Institution - 156
Springfield Oregon, 97477, United States More Info
Site 156
Contact
Abramson Cancer Center Of The University Of Pennsylvania
Philadelphia Pennsylvania, 19066, United States More Info
Jakub Svoboda, Site 170
Contact
215-614-1846
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States More Info
Nadia Khan, Site 148
Contact
215-728-3639
Cancer Care Associates of York
York Pennsylvania, 17403, United States
Cancer Care Associates of York
York Pennsylvania, 17403, United States More Info
Chanh Huynh, Site 117
Contact
Charleston Oncology, P.A
Charleston South Carolina, 29414, United States
Thompson Cancer Survival Center
Knoxville Tennessee, 37916, United States
MD Anderson Cancer Center
Houston Texas, 77003, United States More Info
Dai Chihara, Site 102
Contact
Renovatio Clinical (Millennium Physicians Woodlands)
The Woodlands Texas, 77380, United States More Info
Jonathan Lu, Site 103
Contact
Renovatio Clinical (Millennium Physicians Woodlands)
The Woodlands Texas, 77389, United States
Texas Oncology, P.A. - Tyler
Tyler Texas, 75702, United States More Info
Habte Yimer, Site 161
Contact
903-596-9425
Benaroya Research Institute At Virginia Mason
Seattle Washington, 98101, United States More Info
David Aboulafia, Site 150
Contact
206-223-6193
MultiCare Institute for Research and Innovation
Tacoma Washington, 98405, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

1000

Study ID:

NCT04982471

Recruitment Status:

Recruiting

Sponsor:


Celgene

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.